The National Institute of Health (NIH) is ramping up efforts to improve treatments for genital herpes with a new funding opportunity. Current treatment options are limited, often failing to completely stop viral shedding or prevent recurring outbreaks, and drug resistance is a growing concern for long-term therapies. This initiative invites innovative research into new antiviral drugs, monoclonal antibodies, therapeutic vaccines, and cutting-edge technologies like CRISPR, aiming to target the latent herpes virus and reduce transmission risks. By exploring these novel strategies, the NIH hopes to address gaps in existing treatment, potentially leading to more effective therapies for people living with genital herpes.
This notice of funding opportunity (NOFO) uses a phased award system (R21/R33) to support high-risk, high-reward research, ensuring progress is milestone-driven, with up to five years of funding. While the R21 phase focuses on early development, projects showing promise may progress to the R33 phase for further validation and refinement.
This is an exciting opportunity for researchers to contribute to a field with significant unmet medical needs. By fostering new treatment approaches, this program could lead to breakthroughs in reducing HSV transmission, recurrence, and improving quality of life for those affected.
For more information, check out the official NIH announcement.
Give Today and Join the Fight →
Every donation – whether $10 or $10,000 – moves us closer to a world where herpes is effectively treated and free from stigma.
Questions about giving? Contact us at info@herpescureadvocacy.com or 267-797-7139.
Want the latest news on herpes cure, treatment and prevention?
Sign up for our newsletter and make sure you never miss a thing.
